GlassScriptPhysician profile
S Satheesha Kumar
NPI 1861425605
$2,715.93
in general payments reported to CMS, 2019-2025
19 companies · $655 in 2025
The $655 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150 · 2020: $99.51 · 2021: $308 · 2022: $545 · 2023: $374 · 2024: $584 · 2025: $655.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,614.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,613.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,424.20 | 2021-2025 | Aveir, Gallant, Triclip |
| Medtronic Vascular, INC. | $231.23 | 2019-2020 | |
| Edwards Lifesciences Corporation | $185.37 | 2024 | Mitris Resilia Mitral Valve |
| Novartis Pharmaceuticals Corporation | $178.53 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $136.67 | 2024-2025 | Eliquis, Camzyos |
| Irhythm Technologies, INC. | $91.11 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Baxter Healthcare | $90.07 | 2024-2025 | Hillrom - Carnation Ambulatory Monitor |
| Pfizer INC. | $89.92 | 2023-2024 | |
| Heartflow, INC. | $51.30 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $37.43 | 2025 | Opsumit, Uptravi |
| Medtronic, INC. | $34.44 | 2024 | Symplicity G3 |
| Kestra Medical Technology Services, INC. | $28.83 | 2025 | Assure Wcd |
| Bridgebio Pharma, INC. | $28.10 | 2025 | Attruby |
| Chiesi USA, INC. | $22.31 | 2023 | Kengreal, Cleviprex |
| Amgen INC. | $19.95 | 2024 | Repatha |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| American Regent | $18.79 | 2025 | Injectafer |
| Lundbeck LLC | $18.31 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.18 | 2025 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $13.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw S Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.